Verity (ver-ə-tē): the quality or state of being true, real, or accurate
“VERITY” is a designated clinical study name for a prospective, multi-center trial focused on validating the performance and clinical utility of the OncodeAi-Breast CED platform for early breast cancer detection. Standing for “Validation of Early-stage bReast cancer detectIon TechnologY,” VERITY aims to assess the accuracy, sensitivity, specificity, and overall diagnostic value of this minimally invasive, blood-based molecular fingerprinting technology in real-world patient populations. Through rigorous clinical evaluation, the VERITY study seeks to establish OncodeAi-Breast CED as a reliable, accessible, and cost-effective screening tool that can facilitate earlier intervention and improved patient outcomes in breast cancer care.
The Oncodea™ VERITY Study is a groundbreaking clinical research initiative aimed at validating the effectiveness of the OncodeAi™-Breast Cancer Early Detection (CED) platform. This study represents a significant step forward in the fight against breast cancer by focusing on early detection, which is critical for improving patient outcomes and quality of life.
Why Early Detection Matters
Early Detection of Breast Cancer (EDBC) assays are a revolutionary advancement in molecular diagnostics. These tests have the potential to identify breast cancer in individuals who show no symptoms, enabling treatment to begin at earlier stages when the disease is more responsive. Early intervention can lead to better survival rates and improved quality of life for patients.
However, despite their promise, current EDBC assays face challenges, including:
- Limited understanding of their benefits versus risks.
- Unclear clinical pathways for follow-up after a positive test result.
- The need to integrate these assays with traditional cancer screening methods.
The Goal of the VERITY Study
The VERITY Study is a prospective clinical validation of the OncodeAi™-Breast CED platform. Its primary aim is to demonstrate the platform’s ability to:
- Accurately detect early-stage breast cancer in asymptomatic individuals.
- Provide actionable insights for clinical decision-making.
- Integrate seamlessly with existing cancer screening programs.
By addressing the evidentiary gaps in current EDBC assays, the VERITY Study seeks to pave the way for a new era of breast cancer screening—one that is more effective, accessible, and patient-friendly.
A Vision for the Future
The VERITY Study and the OncodeAi™-Breast CED platform represent a transformative approach to breast cancer detection. By combining advanced technology with a focus on accessibility and accuracy, this initiative has the potential to save lives and redefine how breast cancer is diagnosed and treated.
For more information about the VERITY Study and its mission to advance early detection of breast cancer, stay tuned for updates or contact Oncodea™. Together, we can make a difference in the fight against breast cancer.
